Navigation Links
Relmada Therapeutics Announces LevoCap ER Development Progress
Date:3/4/2013

BLUE BELL, Pa., March 4, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the approval of the application of a Clinical Trial Authorization (CTA) that was submitted with the Medicine and Health Regulatory Agency (MHRA) to conduct a Phase I pharmacokinetic study with the development product abuse-deterrent LevoCap extended release (ER) capsules.  The MHRA is the UK government agency which is responsible for ensuring that medicines and medical devices work and are acceptably safe.

This Phase I safety study is designed to assess the bioavailability and dose proportionality of three levorphanol extended release (ER) formulations, how these compare with a marketed IR (immediate release) product available in the US, and whether there are any differences under fed and fasted conditions.

"This significant progress is in line with the development plan of LevoCap ER. If this study shows positive results, then we will be on track to enter the phase III program in the fourth quarter," said Sergio Traversa , CEO of Relmada.

LevoCap ER, Relmada's lead product is intended to add a powerful new tool to treat pain where opioids alone or non-opioids alone do not provide adequate relief.  Unlike other opioids, levorphanol, the active ingredient in LevoCap ER modulates pain through both opioid pathways and noradrenergic pathways thereby providing pain relief through multiple mechanisms in one capsule. Levorphanol has also been shown to partially reverse analgesic tolerance to morphine and may therefore benefit patients who are tolerant to the analgesic effects of their current opioid. 

Based on its pharmacological profile, LevoCap alone should demonstrate improved efficacy in a broader patient population compared to other opioids.  This includes the vast category of patients affected by chronic pain with combined nociceptive and neuropathic components, which frequently require treatment with two or more pain medications to achieve efficacy. 

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company focused on developing both novel versions of proven drugs and new molecules that potentially address high unmet medical needs in the treatment of chronic pain.  The Company has a deep and diversified portfolio of four lead products at different stages of development and an early stage pipeline of an additional three products. 

For more information, contact:

Visit our website at www.relmada.com



'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
2. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
3. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
4. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
5. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
6. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
7. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
8. Frost & Sullivan Recognizes KAERs Game-Changing Innovating Aerosol Drug Delivery Methods for High-Dose Respiratory Disease Therapeutics
9. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
10. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
11. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Stealth BioTherapeutics Inc. ( Stealth ), a ... today announced new additions to its senior leadership team: ... Officer, and Daniel Geffken as interim Chief ... Carr , Pharm.D. has been promoted to Chief Clinical ... welcome Doug and Daniel to our management team, as ...
(Date:1/19/2017)... January 19, 2017 ... Oncology & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to ... from touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... 2017 Pfizer joins Astex, ... Therapeutics Consortium   Major research investment ...   The Milner Therapeutics Institute ... as a partner to the Milner Therapeutics Consortium. Pfizer ... efficient transfer of materials between industry and academia and ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Pastor and Overseer at The House of Yahweh has posted a new publication this week ... is a time like no other and society needs to understand the only way to ... not want to sound like an old bible beater because religion has a bad rap ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin ... alternative VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic ... during your workout. , After a successful launch in Sweden last year, the ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a ... Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and ... to school and at 19 years of age, he joined the Navy and got married ...
Breaking Medicine News(10 mins):